Palisade Bio Announces 1-for-15 Reverse Stock Split
April 03, 2024 17:30 ET
|
Palisade Bio, Inc.
Carlsbad, CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and...
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
March 26, 2024 08:30 ET
|
Dyadic International, Inc.
The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO. ...
Biopharmaceutical Market Size Worth USD 1651.4 Billion in 2032 | Emergen Research
January 15, 2024 11:00 ET
|
Emergen Research
Vancouver, Jan. 15, 2024 (GLOBE NEWSWIRE) -- The global biopharmaceutical market size was USD 411.4 Billion in 2022 and is expected to register a rapid revenue CAGR of 15.2% during the forecast...
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
November 27, 2023 08:35 ET
|
GRI Bio, Inc.
Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end Currently available treatments for IPF are limited to...
[Latest] Global Acne Treatment Market Size/Share Worth USD 18.77 Billion by 2032 at a 6.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
November 22, 2023 23:30 ET
|
Custom Market Insights
Austin, TX, USA, Nov. 23, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Acne Treatment Market Size, Trends and Insights By Product Type (Topical...
GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases
October 31, 2023 08:45 ET
|
GRI Bio, Inc.
Data presented at the 7th Annual Antifibrotic Drug Development (AFDD) Summit Company’s lead program, GRI-0621, has demonstrated ability to inhibit the activity of type I invariant NKT (iNKT) cells...
GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR
August 23, 2023 09:00 ET
|
GRI Bio, Inc.
Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside of Europe and licensor rights for the EU Aardvark to leverage ADAIR formulation...
Asthma Treatment Market Predicted to Reach USD 34.5 billion, Globally, by 2031 to Grow at a CAGR of 3.7% | Exclusive Report by Transparency Market Research Inc.
August 15, 2023 06:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global asthma treatment market is projected to flourish at a CAGR of 3.7% from 2022 to...
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event
July 24, 2023 09:00 ET
|
GRI Bio, Inc.
- Live moderated webcast with members of the GRI Bio management team on Thursday, July 27th at 1:00 PM ET LA JOLLA, CA, July 24, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio”...
GRI Bio (NASDAQ: GRI) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
June 15, 2023 08:45 ET
|
GRI Bio, Inc.
- Live webcast fireside chat on Thursday, June 22nd at 12:00 PM ET LA JOLLA, CA, June 15, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company...